DE MONITOR - Dé Pharming Expert schreef op 8 juni 2022 10:17:
[...]
Dat was natuurlijk niet het antwoord.
Onderstaand wél het antwoord:
On April 4, 2022, Orchard Therapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market (“Nasdaq”) indicating that the closing bid price of the Company’s American Depository Shares (“ADSs”) was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Select Market.
The notice from Nasdaq has no immediate effect on the listing of the Company’s ADSs, and the ADSs will continue to be listed on the Nasdaq Global Select Market under the symbol “ORTX”.
Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has automatically been afforded a 180-calendar day period, or until October 3, 2022, to regain compliance with the minimum bid price requirement. The continued listing standard will be met if the closing bid price of the Company’s ADSs is at least $1.00 per share for a minimum of ten consecutive business days during the 180-calendar day period. If the Company is not in
compliance by October 3, 2022, the Company may be afforded a second 180-calendar day period to regain compliance if it meets certain requirements.
Kortom: daar komt een RS aan! Dat gaat een flinke kluif worden voor de aandeelhouder van een nog verdere waardedaling van de aandelen. Ook voor Pharming.